Ifetroban

Generic Name: Ifetroban

Drug Type: Small Molecule

Chemical Formula: C_₂₅H_₃₂N_₂O_₅

CAS Number: 143443-90-7

Unique Ingredient Identifier: E833KT807K

Background: Ifetroban has been used in trials studying the treatment of Skin Diseases, Autoimmune Diseases, Pathologic Processes, Scleroderma, Limited, and Scleroderma, Diffuse, among others.

Clinical Trials

Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Phase 2

Recruiting

Conditions: Idiopathic Pulmonary Fibrosis

Interventions: Drug: Ifetroban Sodium
Drug: Placebo

First Posted Date: 2022-10-07

Last Posted Date: 2025-04-17

Lead Sponsor: Cumberland Pharmaceuticals

Target Recruit Count: 128

Registration Number: NCT05571059

Locations: 🇺🇸
University of California San Francisco, San Francisco, California, United States
🇺🇸
Mayo Clinic Jacksonville, Jacksonville, Florida, United States
🇺🇸
Miami VA Health System, Miami, Florida, United States

and more 13 locations

Thromboxane Receptor Antagonist to Improve Endothelial Function

Phase 2

Completed

Conditions: Vascular Dilation
Cardiovascular Diseases

Interventions: Drug: Ifetroban Sodium
Drug: Placebo

First Posted Date: 2019-05-24

Last Posted Date: 2024-12-05

Lead Sponsor: Jeffrey Rade

Target Recruit Count: 57

Registration Number: NCT03962855

Locations: 🇺🇸
University of Massachusetts Medical School, Worcester, Massachusetts, United States

Ifetroban in Treating Patients With Malignant Solid Tumors at High Risk of Metastatic Recurrence

Phase 2

Active, not recruiting

Conditions: Malignant Solid Tumor

Interventions: Other: Placebo
Drug: Ifetroban Sodium

First Posted Date: 2018-10-03

Last Posted Date: 2024-06-27

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 30

Registration Number: NCT03694249

Locations: 🇺🇸
Vanderbilt-Ingram Cancer Center, Nashville, Tennessee, United States

Oral Ifetroban in Subjects with Duchenne Muscular Dystrophy

Phase 2

Active, not recruiting

Conditions: Duchenne Muscular Dystrophy Cardiomyopathy
Cardiomyopathy, Dilated

Interventions: Drug: Ifetroban
Drug: Placebo

First Posted Date: 2017-11-13

Last Posted Date: 2025-02-12

Lead Sponsor: Cumberland Pharmaceuticals

Target Recruit Count: 48

Registration Number: NCT03340675

Locations: 🇺🇸
Arkansas Children's Hospital, Little Rock, Arkansas, United States
🇺🇸
Mattel Children's Hospital, Los Angeles, California, United States
🇺🇸
Children's National Hospital, Washington, District of Columbia, United States

and more 7 locations

Therapeutic Control of Aspirin-Exacerbated Respiratory Disease With Ifetroban

Phase 2

Completed

Conditions: Aspirin-exacerbated Respiratory Disease
Aspirin-Sensitive Asthma With Nasal Polyps
Asthma, Aspirin-Induced
Nasal Polyps

Interventions: Drug: Placebo
Drug: Ifetroban

First Posted Date: 2017-10-30

Last Posted Date: 2023-07-14

Lead Sponsor: Brigham and Women's Hospital

Target Recruit Count: 38

Registration Number: NCT03326063

Locations: 🇺🇸
Asthma Research Center, Brigham and Women's Hospital, Boston, Massachusetts, United States

Oral Ifetroban to Treat Aspirin Exacerbated Respiratory Disease (AERD)

Phase 2

Completed

Conditions: Asthma, Aspirin-Induced

Interventions: Drug: Ifetroban Oral Capsule
Drug: Placebo Oral Capsule

First Posted Date: 2017-01-23

Last Posted Date: 2024-07-10

Lead Sponsor: Cumberland Pharmaceuticals

Target Recruit Count: 54

Registration Number: NCT03028350

Locations: 🇺🇸
Vanderbilt University Medical Center, Nashville, Tennessee, United States
🇺🇸
Emory University School of Medicine, Sinus, Nasal, and Allergy Center, Atlanta, Georgia, United States
🇺🇸
Scripps Clinic - Carmel Valley, San Diego, California, United States

and more 13 locations

Study to Assess Safety and Efficacy of Ifetroban for Treatment of Portal Hypertension in Cirrhotic Patients

Phase 2

Completed

Conditions: Portal Hypertension
Liver Cirrhosis

Interventions: Drug: Placebo
Drug: Ifetroban

First Posted Date: 2016-06-16

Last Posted Date: 2022-01-19

Lead Sponsor: Cumberland Pharmaceuticals

Target Recruit Count: 30

Registration Number: NCT02802228

Locations: 🇺🇸
Tampa General Medical Group, Tampa, Florida, United States
🇺🇸
The Ohio State University Wexner Medical Center, Columbus, Ohio, United States
🇺🇸
Baylor University Medical Center, Dallas, Texas, United States

and more 3 locations

Oral Ifetroban to Treat Diffuse Cutaneous Systemic Sclerosis (SSc) or SSc-associated Pulmonary Arterial Hypertension

Phase 2

Recruiting

Conditions: Scleroderma, Diffuse
Scleroderma, Systemic
Connective Tissue Diseases
Autoimmune Diseases
Scleroderma, Limited
Sclerosis, Progressive Systemic
Skin Diseases
Pathologic Processes

Interventions: Drug: Oral Ifetroban
Drug: Oral Placebo

First Posted Date: 2016-02-15

Last Posted Date: 2024-06-06

Lead Sponsor: Cumberland Pharmaceuticals

Target Recruit Count: 34

Registration Number: NCT02682511

Locations: 🇺🇸
Massachusetts General Hospital, Boston, Massachusetts, United States
🇺🇸
Boston University School of Medicine, Boston, Massachusetts, United States
🇮🇳
KDH - Kokilaben Dhirubhai Ambani Hospital, Mumbai, Maharashtra, India

and more 14 locations

Safety and Pharmacokinetics of Ifetroban in Hepatorenal Syndrome Patients

Phase 2

Completed

Conditions: Hepatorenal Syndrome

Interventions: Drug: Ifetroban Injection
Drug: Placebo

First Posted Date: 2011-09-19

Last Posted Date: 2017-03-01

Lead Sponsor: Cumberland Pharmaceuticals

Target Recruit Count: 55

Registration Number: NCT01436500

Locations: 🇺🇸
Emory University Hospital, Atlanta, Georgia, United States
🇺🇸
UCSD, Hillcrest Medical Center Hospital, La Jolla, California, United States
🇺🇸
Virginia Commonwealth University, Richmond, Virginia, United States

and more 9 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy